English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Giving neoadjuvant chemotherapy allows stage IIB cervical cancer having surgery with a chance of avoiding radiotherapy. Giving neoadjuvant chemotherapy in several studies produces varied responsses. The method for predicting whether a cervical cancer patient experiences responsse of treatment in neoadjuvant chemotherapy becomes important thing, considering the side effects of chemotherapy, time, and cost. Sub-population of cells called Cancer Stem Cells (CSC) is something which is alleged to be responssible for cancer growth, recurrence and the process of resistance to chemotherapy and radiation. Some researchers proved that this occurrence is due to the cancer stem cell which is surviving after chemotherapy. The presence of cervical cancer stem cells is shown by CD44 and ALDH1. This research proves there is connection between the expression of CD44 and ALDH1 as a marker of cancer stem cells with cisplatin neoadjuvant chemotherapy responsse and correlation in the increasing of expression of CD44 and ALDH1 (a marker of cancer stem cells) against cisplatin neoadjuvant chemotherapy resistance in cervical cancer stage IIB. Design observational analytic form prospectively study with total samples 30 patient cervical cancer IIB from December 2016 until May 2017. Clinical and MRI examination and cervical biopsy to immunohistochemistry examination for CD44 and ALDH1. Administration of neoadjuvant chemotherapy (NAC) cisplatin 50 mg/m2 4 times everyweek. After 2–3 weeks after last NAC, repeat to MRI examination. Assesment responsse therapy with RECIST criteria. Chemotherapy responsse obtained Partial Responsse (PR) 12 pts (40%), Stable Dissease (SD) 12 pts (40%), and Progressive Dissease (PD) 6 pts (20%). There is Relationship Strong Negative Correlation Expression CD44 with chemotherapy responsse (Spearman test rs= - 0.903 and p= 0.000); analysis ROC curve obtained cut off 37.00 and 76.00 with accuration 86,67%. Also there is Relationship Strong Negative Correlation Expression ALDH1 with chemotherapy responsse (Spearman test rs= - 0.893 and p= 0.000); analysis ROC curve obtained cut off 55.00 and 94.00 with accuration 93.33%. Analysis with Spearman there is Strong Correlation between CD44 with ALDH1 (rs= 0.907 and p=0.000). And ALDH1 is more better predictor than CD44 to predict chemoterapy responsse (beta coeficient CD44 = -0.389, ALDH1= -0.551). CD44 and ALDH1 expression can be used a predictor of responsse to neoadjuvant chemotherapy cisplatin in patient with cervical cancer IIB; and ALDH1 more better as predictor than CD44. ABSTRAK Pemberian kemoterapi neoadjuvant memungkinkan kanker serviks stadium IIB dapat dilakukan pembedahan dengan kemungkinan menghindari pemberian radioterapi. Pemberian kemoterapi neoadjuvant pada beberapa penelitian memberikan hasil yang bervariatif. Metode untuk memprediksi apakah seseorang penderita kanker serviks mengalami respons terapi pada kemoterapi neoadjuvant menjadi hal yang penting, mengingat efek samping kemoterapi, waktu, dan biaya. Subpopulasi sel yang dinamakan sel punca kanker/cancer stem cells (CSC) tersebutlah yang diduga bertanggung jawab terhadap terjadinya pertumbuhan kanker, kekambuhan, serta proses resistansi terhadap kemoterapi dan radiasi. Beberapa peneliti membuktikan bahwa kejadian seperti ini disebabkan sel punca kanker yang tetap bertahan hidup pasca-kemoterapi. Keberadaan sel punca kanker serviks ditunjukkan oleh CD44 dan ALDH1. Penelitian ini membuktikan adanya hubungan antara ekspresi CD44 dan ALDH1 sebagai penanda sel punca kanker dengan respons kemoterapi neoadjuvant cisplatin; dan terdapat korelasi peningkatan ekspresi CD44 dan ALDH1 (penanda sel punca kanker) terhadap resistansi kemoterapi neoadjuvant cisplatin pada kanker serviks stadium IIB. Penelitian ini menggunakan rancangan analitik observasional secara prospektif dengan jumlah sampel 30 pasien kanker serviks IIB mulai Desember 2016 sampai Mei 2017. Pemeriksaan klinis dan MRI serta biopsi serviks dilakukan, kemudian dilanjutkan pemeriksaan imunohistokimia CD44 dan ALDH1. Pemberian kemoterapi neoadjuvant (NAC) cisplatin 50 mg/m2 dilakukan 4 kali setiap minggu. Setelah 2–3 minggu NAC terakhir pasien dilakukan pemeriksaan ulang klinis ataupun MRI untuk menilai respons terapi secara kriteria RECIST. Respons kemoterapi menunjukkan partial response (PR) 12 subjek (40%), stable dissease (SD) 12 subjek (40%), and progressive dissease (PD) 6 subjek (20%). Terdapat korelasi negatif kuat antara ekspresi CD44 dengan respons terapi (Spearman test rs= - 0,903 dan p= 0,000). Analisis kurva ROC mendapatkan nilai cut off 37,00 dan 76,00 dengan nilai akurasi sebesar 86,67 %. Juga terdapat korelasi negatif kuat antara ekspresi ALDH1 dengan respons terapi (Spearman test rs= - 0,893 and p= 0,000); dilanjutkan analisis kurva ROC didapatkan nilai cut off 55,00 dan 94,00 dengan nilai akurasi sebesar 93,33%. Analisis dengan Spearman didapatkan hubungan korelasi kuat antara ekspresi CD44 dengan ALDH1 (rs= 0,907 dan p=0,000). ALDH1 merupakan prediktor yang lebih baik daripada CD44 (beta coeficient CD44 = -0,389; ALDH1= -0,551). Ekspresi CD44 dan ALDH1 (penanda sel punca kanker) dapat dipakai sebagai prediktor respons kemoterapi neoadjuvant cisplatin pada kanker serviks IIB. ALDH1 merupakan prediktor yang lebih baik daripada CD44

Ekspresi CD44 dan ALDH1 (Penanda Sel Punca Kanker) sebagai Prediktor Respons Kemoterapi Neoadjuvant Cisplatin pada Kanker Serviks Uteri Stadium IIB